The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer

Saad Atiq, Nathan Hirshman, Afreen Shariff, Tian Zhang

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Newly approved systemic treatment options for metastatic urothelial cancer (mUC) have diversified treatments and improved responses and survival for chemotherapy refractory disease. These systemic treatments have associated toxicities which need appropriate management for patients to stay on treatment and potentially have longer benefit from treatment. We review the expected toxicities of immune checkpoint inhibitors, FGFR inhibitors such as erdafitinib, and antibody drug conjugates such as enfortumab vedotin and sacituzumab govitecan.

Original languageEnglish (US)
JournalUrologic Oncology: Seminars and Original Investigations
DOIs
StateAccepted/In press - 2021
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Urology

Fingerprint

Dive into the research topics of 'The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer'. Together they form a unique fingerprint.

Cite this